The promise of individualized therapy has resonated with scientists, healthcare providers, and patients since the inception of the Human Genome Project. The ability to use designer drugs, such as novel monoclonal antibodies and molecularly targeted tyrosine kinase inhibitors, has created a new hope in the management of the cancer patient by individualizing therapy based on the unique molecular mutations in the cancer and the patient's germline DNA. The nuances of implementing germline and somatic genomic testing in a clinical setting are discussed and the future role of pharmacogenomics testing in personalized cancer treatment is examined.
An example of drug-metabolizing gene variants effecting response to a commonly used therapeutic is seen in breast cancer. Estrogen receptor (ER)-positive breast cancers are treated with hormonal therapies that are estrogen antagonists. one such moiety is tamoxifen, which itself has been shown to have altered metabolism due to CYP450 genetic polymorphisms. Tamoxifen and its metabolites compete with estradiol for occupancy of the ER, and in doing so inhibit estrogen-mediated cellular proliferation. Conversion of tamoxifen to its active metabolites occurs predominantly through the CYP450 system and its primary and secondary metabolites are important because they have a greater affinity for the ER than tamoxifen itself (specifically endoxifen has approximately 100 times greater affinity for the ER). Activation of tamoxifen to endoxifen is primarily due to the action of CYP2D6 (see Figure 1) . Therefore, patients with defective CYP2D6 alleles potentially derive less benefit from tamoxifen therapy than patients with functional copies of CYP2D6. The most common null allele among Caucasians is CYP2D6*4, a splice site mutation (G1934A) resulting in loss of enzyme activity, and, therefore, lack of conversion of tamoxifen to its most active metabolite endoxifen. This could result in significantly decreased response to anti-estrogen therapy.
While several retrospective studies have suggested that individuals with loss of function CYP2D6 alleles (ex. CYP2D6*4) have greater rates of tumor recurrence and shorter relapse-free survival; however, other studies have not corroborated these findings. 10 The ongoing debate as to whether CYP2D6 genotype impacts outcomes with tamoxifen was addressed in a large trial from the Breast International Group (BIG) I-98 and Arimidex, Tamoxifen, Alone or in Combination (ATAC) studies where the investigators resolved that CYP2D6 genotyping has no effect. 11, 12 Unfortunately, these studies have come under intense scrutiny due to the departure from Hardy-Weinberg equilibrium of the results. 13 This is thought to be due to errors in the genotyping performed in those studies. More specifically, those studies are said to be biased in terms of genotyping that occurred in tumor tissue DNA instead of germline DNA. The discordant genotype frequencies could most likely be due to known loss of heterozygosity of the CYP2D6 locus in breast tumor tissue and/or the detection of nearby pseudogenes. Accumulating data will need to be re-analyzed and re-assessed in terms of this potential PGXm application.
Another common example of PGXm is seen with the use of Irinotecan (Camptosar © ), a prodrug, that is initially metabolized by carboxylesterases to its active compound, SN-38. SN-38 is inactivated by glucuronidation via the UGT1A1 enzyme to its metabolite SN-38-glucuronide, which is then excreted in the urine (see Figure 2) . A dinucleotide (TA) repeat polymorphism has been identified in the promoter region of the UGT1A1 Table 1 ).
one of the first modern examples of targeted therapy is to be found in the treatment of breast cancer. The human epidermal growth factor-2 (HER2) oncogene encodes a transmembrane receptor, which has been shown to be amplified in up to 35 % of all breast cancers and is associated with a poor prognosis. With such a significant incidence of gene amplification in a common cancer, the HER2 receptor became a focus for therapeutic development. Trastuzumab (Herceptin™) became the first targeted monoclonal antibody therapy in a human solid tumor. Cardiotoxicity was identified as the most severe side effect of this drug and thus breast tumors needed to be tested for HER2 gene amplification and/or overexpression to determine likelihood of response and thus appropriate use of the drug.
14 The FDA approved an immunohistochemistry (IHC) assay for detecting the HER2 receptor in formalin fixed, paraffin embedded (FFPE)
tissue sections and subsequently a fluorescence in situ hybridization (FISH) assay for detecting gene amplification (see Figure 3 ).
More recently, targeted therapies in lung cancer, colon cancer, and melanoma have been successfully developed based on several tumor cell proliferative/survival pathways and their known genetic variation in targeted pathway proteins. [15] [16] [17] [18] The epidermal growth factor receptor (EGFR)
pathway has been implicated in many human cancers and the EGFR gene contains both sensitizing (activating) mutations and resistance mutations (see Figure 4 ). (G13D) mutation may have partial response to the addition of cetuximab to first-line chemotherapy. 21 Similarly, the MAP kinase pathway is being targeted in melanoma with inhibitors to BRAF and MEK.
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Therapeutic Targeting in Human Cancers
While cancer is considered a complex, polygenic, and multifactorial disease, there are hallmarks that are similar between most cancer cells.
These characteristics include the ability to enable uncontrolled cell replication, induction of angiogenesis, genome instability, and resistance to apoptosis. 24 The initiating events for many of these characteristics more commonly include somatic mutations to several genes and in some cases of hereditary cancers, germline mutations to other single genes.
Germline variants can be easily detected in DNA isolated from blood, buccal swabs, or saliva. Identification of variants associated with targeted therapy response and eligibility are more often somatic and typically detected in DNA extracted from tumor cells in a diagnostic specimen such as a cytology fine needle aspirate, biopsy, or resected tumor tissue.
In most cases, the tissue has been processed for histology and exists as FFPE tissue blocks.
FFPE specimens are used routinely for molecular genetic analysis and do not usually pose a problem for such testing. However, the type and amount This can be described as inter-and intra-tumor heterogeneity. Inter-tumor heterogeneity refers to the differences in genetic variation seen in similar tumors from different patients. Intra-tumor heterogeneity refers to the genetic differences observed in tumor cells from the same individual. 25 In a given specimen, there is the potential to have a heterogeneous population of tumor cells, some of which may or may not harbor the same mutation profile as the rest of the tumor. Both tissue and tumor heterogeneity can impact the result of genetic analyses. 
Technologic Advances
Clearly the discussion of personalized medicine would not be occurring if it were not for the rapid advances in genomic technologies. software packages. For oncology, the ability to sequence a targeted number of genes whose mutations are known to be therapeutically important will allow the laboratory to provide massive amounts of critical information from which the oncologist can then design a therapeutic management approach (see Figure 5) . The more traditional model of a single biomarker test result being used to select oncology treatments, monitor the effects of those therapies, and switch therapies as treatment resistance emerges is no longer optimal.
Reflex testing from one gene or panel of mutations to the next as part of a pathway analysis is becoming cost prohibitive and results in delayed turnaround times. In order to predict whether a certain drug/monoclonal will be effective in a particular tumor setting requires a more complex analysis so that the results taken as a whole can more accurately predict therapeutic outcomes.
The Need For Multi-targeted Therapies
As a complex yet common disease, cancer is amongst the main causes of morbidity and mortality worldwide, but especially so in developed countries. 
Companion Diagnostics
Mutation analysis as a precursor to implementation of targeted therapy has become the standard of care for certain tumor types. The FDA has recognized the need for and importance of the 'companion' diagnostic.
Recently, the agency has been forthcoming with FDA-approved assays that can select patients for treatment with certain targeted therapies. Table 2 ).
Future Directions
Recent genomic advances have been welcomed by the oncology community as the potential of bringing cancer drugs to market more rapidly, improving patient outcomes, and making personalized cancer therapy is realized. It can be argued that these changes, mark the transition from the 'Dark Ages' to the 'Renaissance' in oncology. It is anticipated that laboratory analysis of human cancers will become more complex, within which will come the information needed to more effectively treat cancer patients with the true hope of eradicating the disease. n
